Adial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business Update
Adial Pharmaceuticals, Inc (ADIL)
US:NASDAQ Investor Relations:
adialpharma.com
Company Research
Source: GlobeNewswire
Received Favorable Feedback from US and EU Regulatory Agencies Advancing Discussions with Potential Strategic Partners Received $4.3 Million in Gross Proceeds from Warrant Exercises Subsequent to Year-End 2023 GLEN ALLEN, Va., April 02, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders, today provided a business update and reported its financial results for the 2023 fiscal year ended December 31, 2023. Cary Claiborne, President and Chief Executive Officer of Adial, stated, “Throughout 2023 we made important progress that provided us with a clearer path forward to the potential approval and commercial launch of our lead investigational new drug product, AD04, to treat Alcohol Use Disorder, along with our companion diagnostic. Specifically, we conducted meetings and received favorable fee
Show less
Read more
Impact Snapshot
Event Time:
ADIL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADIL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADIL alerts
High impacting Adial Pharmaceuticals, Inc news events
Weekly update
A roundup of the hottest topics
ADIL
News
- EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent [Yahoo! Finance]Yahoo! Finance
- Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark Office [Yahoo! Finance]Yahoo! Finance
- Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark OfficeGlobeNewswire
- Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use Disorder [Yahoo! Finance]Yahoo! Finance
- Adial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use DisorderGlobeNewswire
ADIL
Sec Filings
- 4/26/24 - Form 8-K
- 4/23/24 - Form 424B3
- 4/22/24 - Form EFFECT
- ADIL's page on the SEC website